1. Home
  2. RXRX vs ADNT Comparison

RXRX vs ADNT Comparison

Compare RXRX & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXRX
  • ADNT
  • Stock Information
  • Founded
  • RXRX 2013
  • ADNT 2016
  • Country
  • RXRX United States
  • ADNT Ireland
  • Employees
  • RXRX N/A
  • ADNT N/A
  • Industry
  • RXRX Biotechnology: Pharmaceutical Preparations
  • ADNT Auto Parts:O.E.M.
  • Sector
  • RXRX Health Care
  • ADNT Consumer Discretionary
  • Exchange
  • RXRX Nasdaq
  • ADNT Nasdaq
  • Market Cap
  • RXRX 2.0B
  • ADNT 1.3B
  • IPO Year
  • RXRX 2021
  • ADNT N/A
  • Fundamental
  • Price
  • RXRX $5.21
  • ADNT $22.18
  • Analyst Decision
  • RXRX Buy
  • ADNT Hold
  • Analyst Count
  • RXRX 5
  • ADNT 9
  • Target Price
  • RXRX $7.00
  • ADNT $17.31
  • AVG Volume (30 Days)
  • RXRX 33.3M
  • ADNT 1.5M
  • Earning Date
  • RXRX 08-07-2025
  • ADNT 08-05-2025
  • Dividend Yield
  • RXRX N/A
  • ADNT N/A
  • EPS Growth
  • RXRX N/A
  • ADNT N/A
  • EPS
  • RXRX N/A
  • ADNT N/A
  • Revenue
  • RXRX $59,790,000.00
  • ADNT $14,384,000,000.00
  • Revenue This Year
  • RXRX $23.51
  • ADNT N/A
  • Revenue Next Year
  • RXRX $53.87
  • ADNT N/A
  • P/E Ratio
  • RXRX N/A
  • ADNT N/A
  • Revenue Growth
  • RXRX 29.32
  • ADNT N/A
  • 52 Week Low
  • RXRX $3.79
  • ADNT $10.04
  • 52 Week High
  • RXRX $12.36
  • ADNT $26.59
  • Technical
  • Relative Strength Index (RSI)
  • RXRX 54.08
  • ADNT 82.50
  • Support Level
  • RXRX $4.91
  • ADNT $19.31
  • Resistance Level
  • RXRX $5.44
  • ADNT $19.91
  • Average True Range (ATR)
  • RXRX 0.37
  • ADNT 0.70
  • MACD
  • RXRX 0.01
  • ADNT 0.17
  • Stochastic Oscillator
  • RXRX 64.47
  • ADNT 93.90

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.

Share on Social Networks: